HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: jnumed.108.052316v1 49/9/1472    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Eiblmaier, M. Articles by Anderson, C. J. PubMed PubMed Citation Articles by Eiblmaier, M. Articles by Anderson, C. J.

Correlating EGFR Expression with Receptor-Binding Properties and Internalization of ⁶⁴Cu-DOTA-Cetuximab in 5 Cervical Cancer Cell Lines

¹ Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri; ² Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri; ³ Department of Medicine, Washington University School of Medicine, St. Louis, Missouri; ⁴ Department of Biochemistry, Washington University School of Medicine, St. Louis, Missouri; and ⁵ Department of Chemistry, Washington University School of Medicine, St. Louis, Missouri

Correspondence: For correspondence or reprints contact: Carolyn J. Anderson, Mallinckrodt Institute of Radiology, 510 S. Kingshighway Blvd., Campus Box 8225, St. Louis, MO 63110. E-mail: andersoncj{at}wustl.edu

The anti–epidermal growth factor receptor (anti-EGFR) antibody cetuximab is clinically approved for the treatment of EGFR-expressing metastatic colorectal cancer and advanced head and neck cancer. Overexpression of EGFR has also been found in more than 70% of carcinomas of the cervix. The overall goal of this study was to determine whether ⁶⁴Cu-1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-cetuximab has potential as an agent for measuring EGFR concentration by PET imaging in cervical cancer tumors. Methods: Cetuximab was conjugated to the bifunctional chelator DOTA and labeled with ⁶⁴Cu. EGFR messenger RNA (mRNA) expression was correlated with EGFR densities on the cell surface of 5 different cervical cancer cell lines and with receptor function, measured by internalization of ⁶⁴Cu-DOTA-cetuximab. Imaging in tumor-bearing mice with small-animal PET was performed using the highest-expressing cervical cancer cell line. Results: The affinity of ⁶⁴Cu-DOTA-cetuximab binding for the EGFR was similar in 4 EGFR-positive lines, varying from 0.1 to 0.7 nM. The mRNA expression corresponded well with EGFR densities and levels of internalization, with responses decreasing in the order of CaSki > ME-180 > DoTc2 4510 > HeLa > C-33A. Biodistribution and small-animal PET studies with ⁶⁴Cu-DOTA-cetuximab in CaSki tumor-bearing nude mice showed relatively high tumor uptake at 24 h after injection (13.2 ± 1.2 percentage of injected activity per gram), although there was also significant retention of activity in the blood and liver accumulation. Conclusion: ⁶⁴Cu-DOTA-cetuximab was successfully used to detect and quantify EGFR expression in cervical cancer tumors, and small-animal PET/CT of EGFR-expressing CaSki tumors suggests potential for PET/CT of EGFR-positive tumors.

Key Words: ⁶⁴Cu • cervical cancer • cetuximab

COPYRIGHT © 2008 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2008 49: 11A-12A. [Full Text]